1What Part 210 does.
Part 210 is titled “Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general”, and it has three sections.¹
- 210.1, status. The regulations in Parts 210, 211, 213, 225 and 226 “contain the minimum current good manufacturing practice” for the methods, facilities and controls used to make, process, pack or hold a drug, so that it meets the Act’s requirements as to safety and has the identity, strength, quality and purity it is represented to have. Failing to comply renders the drug adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act, and both the drug and the person responsible are subject to regulatory action.
- 210.2, applicability. The drug CGMP parts, the biologics regulations in Parts 600 to 680 and the tissue regulations in Part 1271 supplement rather than supersede each other, and where they conflict the more specific rule wins. A company that performs only some operations need comply only with the rules for those operations. Production of an investigational drug for a phase 1 study is exempt from Part 211 until the drug has been made available for a phase 2 or phase 3 study or lawfully marketed.
- 210.3, definitions. Terms used across Parts 211, 225 and 226, including batch, component, drug product, active ingredient, lot, lot number, quality control unit, strength, theoretical and actual yield, acceptance criteria and representative sample.
Part 210 has no operating requirements of its own. Its job is to say what the CGMP regulations are, whom they bind and what their words mean.¹
2What Part 211 requires.
Part 211, “Current good manufacturing practice for finished pharmaceuticals”, contains “the minimum current good manufacturing practice for preparation of drug products” for humans or animals, excluding positron emission tomography drugs and medical gases, which have their own Parts 212 and 213.²³⁴ It uses the definitions in 210.3.² Its eleven subparts follow a product from the people and buildings that make it to the records that prove how it was made.
| Subpart | What it covers | Key sections |
|---|---|---|
| A, General provisions | Scope and definitions | 211.1, 211.3 |
| B, Organization and personnel | The quality control unit, qualifications, responsibilities, consultants | 211.22, 211.25 |
| C, Buildings and facilities | Design, lighting, ventilation, plumbing, sanitation, maintenance | 211.42, 211.46 |
| D, Equipment | Design, construction, cleaning and maintenance, automatic and electronic equipment, filters | 211.67, 211.68 |
| E, Control of components and drug product containers and closures | Receipt, quarantine, testing, approval or rejection, retesting | 211.84 |
| F, Production and process controls | Written procedures and deviations, yield, in-process testing, time limits, microbial contamination, reprocessing | 211.100, 211.110, 211.113 |
| G, Packaging and labeling control | Labelling issuance, packaging operations, tamper-evident packaging, inspection, expiration dating | 211.130, 211.137 |
| H, Holding and distribution | Warehousing and distribution procedures | 211.142, 211.150 |
| I, Laboratory controls | General requirements, testing and release, stability, reserve samples | 211.160, 211.165, 211.166, 211.170 |
| J, Records and reports | Record retention, equipment logs, master and batch records, record review, laboratory records, complaints | 211.180, 211.186, 211.188, 211.192, 211.194, 211.198 |
| K, Returned and salvaged drug products | Returns and salvaging | 211.204, 211.208 |
3Six sections in detail.
What the regulation requires in six of the sections:²
- 211.22, quality control unit. A quality control unit has “the responsibility and authority to approve or reject” all components, containers, closures, in-process materials, packaging, labelling and drug products, and to review production records. It approves or rejects every procedure or specification that affects identity, strength, quality and purity, and its responsibilities are in writing.
- 211.68, automatic, mechanical and electronic equipment. Computers and related systems may be used if they perform satisfactorily. They are routinely calibrated, inspected or checked under a written programme, only authorised people may change master records, input and output are checked for accuracy, and a backup is kept.
- 211.100, written procedures and deviations. Production and process control procedures are in writing, drafted and approved by the responsible units, and reviewed and approved by the quality control unit. They are followed and documented “at the time of performance”. Any deviation “shall be recorded and justified”.
- 211.166, stability testing. A written stability programme, with statistically based sample sizes and test intervals and reliable, specific methods, assesses each product’s stability, and its results are used to set storage conditions and expiration dates.
- 211.192, production record review. The quality control unit reviews and approves all production and control records before a batch is released or distributed. Any unexplained discrepancy or failure to meet specifications is “thoroughly investigated, whether or not the batch has already been distributed”, the investigation extends to other batches that may be affected, and its conclusions and follow-up are written down.
- 211.194, laboratory records. Laboratory records hold “complete data derived from all tests”, including the sample, the method, a complete record of the data from each test with its graphs, charts and spectra, the calculations, the results against specifications, the analyst and a second person’s review.
4How they fit with other rules.
Part 211 applies to drug products, which 210.3 defines as finished dosage forms such as tablets, capsules and solutions.¹ Active pharmaceutical ingredients are still subject to the statutory CGMP requirement in section 501(a)(2)(B),⁵ and FDA points to ICH Q7 as its CGMP guidance for API manufacture.⁶ For drugs that are also biological products, Parts 600 to 680 apply alongside Part 211.²
Records kept electronically to meet Part 211 also fall under 21 CFR Part 11, which applies to electronic records kept under any of FDA’s records requirements.⁷ FDA’s question-and-answer resource on CGMP requirements clarifies Part 211 topic by topic, under headings that follow its subparts. FDA classes it as Level 2 guidance,⁸ the level that sets out existing practices or minor changes in interpretation or policy.⁹
The regulations are binding; the guidance is not. Under FDA’s good guidance practices regulation, guidance documents “do not establish legally enforceable rights or responsibilities” and do not legally bind the public or FDA. A company may take another approach, but it must still comply with the statutes and regulations.⁹
5How it runs in Seal.
In Seal the master production record is an executable workflow rather than a document. The electronic batch records blueprint checks materials, equipment, training, limits and signatures as each step runs, opens an exception from the step where it occurs and starts review while the batch is still running, with the full record available to QA.
The pharmaceutical manufacturing blueprint carries the same record from receipt to release. Quarantine, approved, restricted, rejected and expired states control which operations may use a material lot, and an overdue calibration or failed cleaning verification prevents normal use of a piece of equipment. Regulatory and validation covers the audit trails and electronic signatures that support Part 11 and Annex 11.
References
- 121 CFR Part 210, Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general, sections 210.1 to 210.3, eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 210 (read 6 November 2026) - 221 CFR Part 211, Current good manufacturing practice for finished pharmaceuticals, eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 211 (read 6 November 2026) - 321 CFR Part 212, Current good manufacturing practice for positron emission tomography drugs, eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 212 (read 6 November 2026) - 421 CFR Part 213, Current good manufacturing practice for medical gases, eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 213 (read 6 November 2026) - 5Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, draft guidance for industry, FDA, March 2026, footnote 8. https:/
/ www. fda. gov/ regulatory- information/ search- fda- guidance- documents/ responding- fda- form- 483- observations- conclusion- drug- cgmp- inspection (read 6 November 2026) - 6Overview of Drug Manufacturing Inspections, Understanding FDA Inspections and Data Webinar, FDA, 6 September 2023. https:/
/ www. fda. gov/ media/ 172786/ download (read 6 November 2026) - 721 CFR 11.1, Scope, eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- A/ part- 11/ subpart- A/ section- 11. 1 (read 6 November 2026) - 8Q&A on CGMP Requirements, FDA, content current as of 21 November 2025. https:/
/ www. fda. gov/ drugs/ pharmaceutical- quality- resources/ qa- cgmp- requirements (read 6 November 2026) - 921 CFR 10.115, Good guidance practices, paragraphs (c) and (d), eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- A/ part- 10/ subpart- B/ section- 10. 115 (read 6 November 2026)
AQuestions and answers
Does Part 211 apply to active pharmaceutical ingredients?
Part 211 applies to drug products, meaning finished dosage forms. API manufacturers are still bound by the statutory requirement to follow current good manufacturing practice, and FDA uses ICH Q7 as its guidance on what that means for APIs.
Does Part 211 apply to clinical trial material?
Production of an investigational drug for a phase 1 study is exempt from Part 211, although the statutory CGMP requirement still applies. Once the drug has been made available for a phase 2 or phase 3 study, or is lawfully marketed, Part 211 applies in full.
How long must Part 211 records be kept?
Production, control and distribution records for a batch are kept for at least one year after the batch’s expiration date. For certain OTC products exempt from expiration dating, the period is three years after distribution.
Does Part 211 require electronic batch records?
No. Part 211 requires a batch production and control record for each batch, with complete information, but does not set the medium. Records may be originals or true copies, and computer systems may be used if they are checked and controlled under 211.68. Electronic records also have to meet Part 11.
What is the difference between a master record and a batch record under Part 211?
The master production and control record, under 211.186, is the approved instructions for each product and batch size, prepared and signed by one person and independently checked by a second. The batch production and control record, under 211.188, is the record of one batch made from it, including an accurate copy of the master record and documentation of each significant step.